Evidence map›Paper›PMID 27737658›Full record

ArticleBMC endocrine disorders2016

The effect of lifestyle intervention in obesity on the soluble form of activated leukocyte cell adhesion molecule.

Alba Sulaj, Johanna Zemva, Ulrike Zech, Annika Woehning, Maik Brune, Gottfried Rudofsky, Peter P Nawroth, Thomas Fleming, Rüdiger von Bauer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alba SulajDepartment of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany. Alba.Sulaj@med.uni-heidelberg.de.
Johanna ZemvaDepartment of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
Ulrike ZechDepartment of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
Annika WoehningDepartment of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
Maik BruneDepartment of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
Gottfried RudofskyDepartment of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
Peter P NawrothDepartment of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
Thomas FlemingDepartment of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
Rüdiger von BauerDepartment of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to investigate the effect of a lifestyle intervention in obesity on the soluble form of the activated leukocyte cell adhesion molecule (sALCAM) and its association with metabolic parameters.

methodsTwenty-nine obese subjects selected from the OPTIFAST®52 program. This program consisted into 2 crucial phases: an initial 12-week active weight reduction phase, followed by a 40-week weight maintenance phase. At baseline, after 12 weeks and at the end of the program, fasting glucose and insulin, total cholesterol, LDL-C, HDL-C, triglycerides, adiponectin, leptin, high sensitivity CRP, sALCAM, homeostasis model assessment-estimated insulin resistance (HOMA-IR) and leptin-to-adiponectin-ratio were determined. Oral glucose tolerance test (OGTT) was performed when indicated.

resultsAt baseline, the serum concentration of sALCAM was increased and correlated positively with HOMA-IR and negatively with age. At the end of the program, sALCAM concentrations decreased significantly. Multivariate analysis showed that sALCAM significantly correlated with age, glucose concentration after 2 h OGTT and the HOMA-IR. A higher decrease of HOMA-IR during the study was observed in subjects with higher concentration of sALCAM at baseline.

conclusionssALCAM might be a novel biomarker in obesity that correlates and predicts insulin sensitivity improvement and that can be affected by lifestyle intervention.

Indexed as

Risk Reduction BehaviorActivated-Leukocyte Cell Adhesion MoleculeAdiponectinAdultAge FactorsAntigens, CDBiomarkersBlood GlucoseBody Weight MaintenanceCell Adhesion Molecules, NeuronalCholesterolC-Reactive ProteinFemaleFetal ProteinsGlucose Tolerance TestHomeostasisActivated-Leukocyte Cell Adhesion MoleculeAdiponectinALCAM protein, humanAntigens, CDBiomarkersBlood GlucoseCell Adhesion Molecules, NeuronalCholesterolC-Reactive ProteinFetal ProteinsInsulinLeptinTriglyceridesCell adhesion moleculeInsulin resistanceLifestyle interventionObesitysALCAM

Identifiers

PMID27737658
PMCPMC5064930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.